Experimental HCV Drugs
Experimental HCV Drugs
EASL 2012: Simeprevir (TMC435) Improves Response Rates for Difficult-to-Treat Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Monday, 23 April 2012 00:00
- Written by Liz Highleyman
A combination of simeprevir -- better known as TMC435 -- plus pegylated interferon and ribavirin raised cure rates for genotype 1 hepatitis C patients who did not respond to previous treatment, according to a study presented at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
EASL 2012: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
- Details
- Category: HCV Treatment
- Published on Saturday, 21 April 2012 00:00
- Written by Keith Alcorn and Michael Carter
A real-world study of recently approved hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate of serious adverse events and treatment discontinuations than in clinical trials, Christophe Hézode reported on behalf of the French Compassionate Use of Protease Inhibitors in Cirrhotics (CUPIC) cohort study at the 47th International Liver Congress (EASL 2012) in Barcelona on Thursday.
EASL 2012: Interferon Lambda as Effective as Alfa for Hepatitis C but with Much Better Safety Profile
- Details
- Category: HCV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Michael Carter
A new form of pegylated interferon, interferon lambda, is associated with significantly fewer side effects than the standard form of the drug, interferon alfa, in a study conducted in patients with easier to treat hepatitis C genotypes 2 and 3, researchers reported at the 47th International Liver Congress (EASL 2012) in Barcelona.
EASL 2012: GS-7977, Daclatasvir, and Asunaprevir Look Good in Interferon-Free Regimens for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 20 April 2012 00:00
- Written by Liz Highleyman
Most previously untreated people with chronic hepatitis C virus (HCV) infection achieved an early cure with an all-oral combination of the HCV NS5A replication complex inhibitor daclatasvir (formerly BMS-790052) plus the nucleotide NS5B polymerase inhibitor GS-7977, researchers reported this week at the 47th International Liver Congress (EASL 2012) in Barcelona. Another study confirmed that daclatasvir plus the HCV protease inhibitor asunaprevir (formerly BMS-650032) produces a long-term cure for a large proportion of difficult-to-treat patients.
IRES Inhibitor Discovery May Offer New Way to Halt Hepatitis C Replication
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 20 March 2012 00:00
- Written by Press Release
Researchers have discovered the structure of a molecule from a class of compounds called benzimidazoles that can attach itself to the internal ribosome entry site (IRES) in the genetic material of hepatitis C virus (HCV) and stop its replication, according to a report in the March 19, 2012, advance online edition of Proceedings of the National Academy of Sciences USA.
More Articles...
- CROI 2012: Studies Look at Interactions Between New Hepatitis C Drugs and HIV Antiretrovirals
- Phase 3 Trials Now Testing HCV Drug TMC435 in Genotype 1 Non-responders and Genotype 4 Patients
- CROI 2012: Interactions between HCV Drug Daclatasvir and HIV Antiretrovirals Are Minimal or Manageable
- CROI 2012: GS-7977 Rapidly Suppresses HCV, but Most Patients Relapse after Stopping Treatment
Web Design and Development by